GSK (LON:GSK) Rating Reiterated by JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating restated by investment analysts at JPMorgan Chase & Co. in a note issued to investors on Tuesday, Digital Look reports.

GSK has been the subject of several other reports. Citigroup reiterated a “buy” rating and set a GBX 2,100 ($26.56) price objective on shares of GSK in a report on Monday, June 24th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 ($26.56) price target on shares of GSK in a research note on Thursday, June 27th. Barclays reiterated an “equal weight” rating and set a GBX 1,725 ($21.82) price target on shares of GSK in a report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,950 ($24.66) price objective on shares of GSK in a report on Friday. Finally, Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Thursday, June 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of GBX 1,791.25 ($22.66).

GSK Stock Down 1.3 %

GSK stock opened at GBX 1,506.50 ($19.06) on Tuesday. GSK has a twelve month low of GBX 1,302.60 ($16.48) and a twelve month high of GBX 1,823.50 ($23.06). The company has a debt-to-equity ratio of 134.34, a quick ratio of 0.73 and a current ratio of 0.87. The firm has a market cap of £61.47 billion, a PE ratio of 1,382.11, a P/E/G ratio of 1.19 and a beta of 0.27. The firm’s 50 day moving average price is GBX 1,685.84 and its two-hundred day moving average price is GBX 1,632.29.

Insider Buying and Selling at GSK

In other news, insider Wendy Becker purchased 446 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was bought at an average cost of GBX 1,614 ($20.41) per share, for a total transaction of £7,198.44 ($9,105.03). Corporate insiders own 1.60% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.